Our internationally recognised publications give you access to the expertise of hundreds of the world’s leading scientists, experts and researchers.

Our unrivalled collection of publications spans evidence-based clinical knowledge, research and regulatory information. The extensive breadth of content on MedicinesComplete supports your decision making, from research to the point of care and provides you with the world’s most trusted resources.

We’re excited to announce the launch of two new resources: Martindale’s ADR Checker, a quick and easy tool to support you when managing patients with adverse drug reactions, and the Palliative Care Formulary, the expert source of drug information in palliative and hospice care.

Subscribe Publication Updates

Publication Updates

10 Nov
Stockleys Drug Interactions_logo
Stockley’s Drug Interactions November 2020 Update

Stockley’s Drug Interactions update with new and revised monographs.

This update includes the addition of letermovir, and the monographs for sugammadex have been fully revised and updated. There are 12 new monographs and 10 revised monographs in this update.

10 Nov
Palliative Care Formulary November 2020 Update

This update contains 2 revised monographs.

The following monographs have been fully revised: Drugs for diabetes mellitus; Oxcarbazepine.

10 Nov
Stockley's Interactions Checker_logo
Stockley’s Interactions Checker November 2020 Update

New and updated interactions now available

For November, 250 new interactions have been added, and 81 existing interactions have been updated.

10 Nov
British National Formulary for Children logo
BNF for Children November 2020 Update

This update contains 10 significant changes, 2 dose changes and 2 new monographs.

Significant Changes:

  • Bedaquiline in combination regimen for multiple-drug resistant pulmonary tuberculosis [AWMSG guidance].
  • Cannabidiol with clobazam for therapy of seizures associated with Dravet syndrome [SMC guidance].
  • Cannabidiol with clobazam for therapy of seizures associated with Lennox-Gastaut syndrome [SMC guidance].
  • Fentanyl transdermal patches for non-cancer pain: do not use in opioid-naive patients [MHRA/CHM advice].
  • Immunoglobulins: updated guidance on the use of varicella-zoster immunoglobulin in-line with Public Health England recommendations.
  • Insulins (all types): risk of cutaneous amyloidosis at injection site [MHRA/CHM advice] (advice in biphasic insulin aspart, biphasic insulin lispro, biphasic isophane insulin, insulin, insulin aspart, insulin degludec, insulin detemir, insulin glargine, insulin glulisine, insulin lispro, isophane insulin; see example in insulin).
  • Methotrexate once-weekly for autoimmune diseases: new measures to reduce risk of fatal overdose due to inadvertent daily instead of weekly dosing [MHRA/CHM advice].
  • Opioids: risk of dependence and addiction [MHRA/CHM advice] (advice in alfentanil, buprenorphine, co-codamol, codeine phosphate, co-phenotrope, diamorphine hydrochloride, dihydrocodeine tartrate, fentanyl, hydromorphone hydrochloride, methadone hydrochloride, morphine, oxycodone hydrochloride, pethidine hydrochloride, remifentanil, tapentadol, tramadol hydrochloride; see example in morphine).
  • Poisoning, emergency treatment: updated guidance on the management of paracetamol poisoning in-line with TOXBASE recommendations.
  • Varicella-zoster vaccine: updated guidance in-line with Public Health England recommendations.

Dose Changes:

  • Glycopyrronium bromide [oral dosing in children updated].
  • Mercaptamine [update to dosing for nephropathic cystinosis].

New Monographs:

  • Kaftrio® [tezacaftor with ivacaftor and elexacaftor].
  • Sirturo® [bedaquiline].

For further details on changes in the BNFC click on
https://www.medicinescomplete.com/#/content/bnfc/PHP107699?hspl=changes

10 Nov
British National Formulary logo
British National Formulary November 2020 Update

This update contains 29 significant changes, 4 dose changes, 7 new monographs and 2 new preparations.

Significant Changes:

  • Andexanet alfa for adults treated with apixaban or rivaroxaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding [SMC guidance].
  • Avelumab with axitinib for untreated advanced renal cell carcinoma [NICE guidance].
  • Bedaquiline in combination regimen for multiple-drug resistant pulmonary tuberculosis [AWMSG guidance].
  • Brolucizumab for the treatment of adults with neovascular (wet) age-related macular degeneration [SMC guidance].
  • Cannabidiol with clobazam for therapy of seizures associated with Dravet syndrome [SMC guidance].
  • Cannabidiol with clobazam for therapy of seizures associated with Lennox-Gastaut syndrome [SMC guidance].
  • Caplacizumab for the treatment of adults with acquired thrombotic thrombocytopenic purpura [SMC guidance].
  • Doravirine in combination with other antiretroviral drugs for the treatment of adults infected with HIV-1 [AWMSG guidance].
  • Esketamine for adults with treatment-resistant major depressive disorder [SMC guidance].
  • Fentanyl transdermal patches for non-cancer pain: do not use in opioid-naive patients [MHRA/CHM advice].
  • Fluocinolone acetonide for prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye [SMC guidance].
  • Gilteritinib for the treatment of adults who have relapsed or refractory acute myeloid leukaemia with a FLT3 mutation [SMC guidance].
  • Immunoglobulins: updated guidance on the use of varicella-zoster immunoglobulin in-line with Public Health England recommendations.
  • Insulins (all types): risk of cutaneous amyloidosis at injection site [MHRA/CHM advice] (advice in biphasic insulin aspart, biphasic insulin lispro, biphasic isophane insulin, insulin, insulin aspart, insulin degludec, insulin detemir, insulin glargine, insulin glulisine, insulin lispro, isophane insulin; see example in insulin).
  • Lamivudine with tenofovir disoproxil and doravirine for the treatment of adults infected with HIV-1 [AWMSG guidance].
  • Methotrexate once-weekly for autoimmune diseases: new measures to reduce risk of fatal overdose due to inadvertent daily instead of weekly dosing [MHRA/CHM advice].
  • Naldemedine for treating opioid-induced constipation [NICE guidance].
  • Opioids: risk of dependence and addiction [MHRA/CHM advice] (advice in alfentanil, buprenorphine, co-codamol, codeine phosphate, co-phenotrope, diamorphine hydrochloride, dihydrocodeine tartrate, fentanyl, hydromorphone hydrochloride, kaolin with morphine, meptazinol, methadone hydrochloride, morphine, oxycodone hydrochloride, pentazocine, pethidine hydrochloride, remifentanil, tapentadol, tramadol hydrochloride; see example in morphine).
  • Osteoporosis: updated guidance on management.
  • Pembrolizumab for the treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma [SMC guidance].
  • Pembrolizumab with axitinib for first-line treatment of advanced renal cell carcinoma [SMC guidance].
  • Pembrolizumab with axitinib for untreated advanced renal cell carcinoma [NICE guidance].
  • Pertuzumab in combination with trastuzumab and chemotherapy for the treatment of adults with HER2-positive early breast cancer [SMC guidance].
  • Poisoning, emergency treatment: updated guidance on the management of paracetamol poisoning in-line with TOXBASE recommendations.
  • Polatuzumab vedotin with rituximab and bendamustine for the treatment of relapsed or refractory diffuse large B-cell lymphoma [NICE and SMC guidance].
  • Semaglutide (Rybelsus®▼) for the treatment of adults with insufficiently controlled type 2 diabetes mellitus [SMC guidance].
  • Sodium zirconium cyclosilicate for the treatment of adults with hyperkalaemia [SMC guidance].
  • Steroid Emergency Card to support early recognition and treatment of adrenal crisis in adults [NHS Improvement Patient Safety Alert] (advice in alclometasone dipropionate, beclometasone dipropionate, benzyl benzoate with bismuth oxide, bismuth subgallate, hydrocortisone acetate, peru balsam and zinc oxide, betamethasone, budesonide, ciclesonide, cinchocaine hydrochloride with fluocortolone caproate and fluocortolone pivalate, cinchocaine with prednisolone, ciprofloxacin with fluocinolone acetonide, clobetasol propionate, clobetasone butyrate, deflazacort, dexamethasone, diflucortolone valerate, fludrocortisone acetate, fludroxycortide, flumetasone pivalate with cliquinol, fluocinolone acetonide, fluocinonide, fluorometholone, fluticasone, gentamicin with hydrocortisone, hydrocortisone, hydrocortisone butyrate, hydrocortisone with lidocaine, hydrocortisone with pramocaine, loteprednol etabonate, methylprednisolone, mometasone furoate, prednisolone, triamcinolone acetonide, triamcinolone hexacetonide; see example in dexamethasone).
  • Varicella-zoster vaccine: updated guidance in-line with Public Health England recommendations.

Dose Changes:

  • Avelumab [dosing information updated].
  • Escitalopram [elderly dosing for panic disorder updated].
  • Mercaptamine [update to dosing for nephropathic cystinosis].
  • Pembrolizumab [dosing information updated].

New Monographs:

  • Daurismo® [glasdegib].
  • Fetcroja® [cefiderocol].
  • Kaftrio® [tezacaftor with ivacaftor and elexacaftor].
  • Nilemdo® [bempedoic acid].
  • Nustendi® [bempedoic acid with ezetimibe].
  • Piqray® [alpelisib].
  • Sunosi® [solriamfetol].

New Preparations: Remsima® solution for injection in pre-filled pens or syringes [infliximab]; Rybelsus®▼ [semaglutide].

For further details on changes in the BNF click on http://www.medicinescomplete.com/mc/bnf/current/PHP107699-changes.htm

10 Nov
Pharmaceutical Excipients logo
Pharmaceutical Excipients November 2020 Update

This update coincides with the publication of the 10th print edition of the Handbook of Pharmaceutical Excipients. It contains 31 updated monographs, 2 new chapters, and 8 new monographs. Hydroxypropyl starch has been renamed to Starch, hydroxypropyl. Pharmacopeias have been globally updated.

New monographs: Arginine hydrochloride; cysteine; cysteine hydrochloride; invert sugar; glycine hydrochloride; sodium bisulfite; sodium phosphate, tribasic; saccharin calcium.

Revised monographs: Acacia; carboxymethyl cellulose calcium; carboxymethyl cellulose sodium; castor oil; ceratonia; cetrimide; cresol; cyclodextrins; dextrates; dextrin; dextrose; dextrose anhydrous; glycerin; lanolin; lanolin, hydrous; magnesium trisilicate; menthol; petrolatum and lanolin alcohols; polyethylene glycol; polyoxyethylene sorbitan fatty acid esters; polyoxyethylene stearates; propylene glycol; pullulan; saccharin sodium; sodium alginate; sodium metabisulfite; sodium sulphite; sorbitan esters (sorbitan fatty acid esters); starch; starch, modified; zein.

View more